Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Puig

Showing results (381-390 of 423) with videos related to

Pageof 43
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|July 7, 2017
Infantile hemangiomas with minimal or arrested growth associated with soft tissue hypertrophy: a case series of 10 patientsS Planas-Ciudad, E Roé Crespo, I Sánchez-Carpintero, et al.
Actas Dermo-Sifiliograficas|August 6, 2014
Immune-mediated inflammatory diseases and other comorbidities in patients with psoriasis: baseline characteristics of patients in the AQUILES studyF Vanaclocha, V Crespo-Erchiga, R Jiménez-Puya, et al.
The British Journal of Dermatology|October 15, 2013
Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)C Paul, L Puig, K Kragballe, et al.
The British Journal of Dermatology|September 18, 2016
Biosimilars for psoriasis: clinical studies to determine similarityA Blauvelt, L Puig, S Chimenti, et al.
The British Journal of Dermatology|October 15, 2013
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasisK Reich, L Puig, C Paul, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 14, 2018
Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissuesJoshua A Kulas, Whitney F Franklin, Nicholas A Smith, et al.
Actas Dermo-Sifiliograficas|May 26, 2009
[Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology]L Puig, X Bordas, J M Carrascosa, et al.
The British Journal of Dermatology|September 19, 2012
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical settingR Navarro, E Vilarrasa, P Herranz, et al.
Environmental Pollution (Barking, Essex : 1987)|May 30, 2018
In utero exposure to fine particulate matter results in an altered neuroimmune phenotype in adult miceJoshua A Kulas, Jordan V Hettwer, Mona Sohrabi, et al.
The British Journal of Dermatology|June 21, 2019
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeksK Reich, R B Warren, L Iversen, et al.
Pageof 43

Showing results (381-390 of 423) with videos related to

Sort By:
Pageof 43
Journal of the European Academy of Dermatology and Venereology : JEADV|July 7, 2017
Infantile hemangiomas with minimal or arrested growth associated with soft tissue hypertrophy: a case series of 10 patientsS Planas-Ciudad, E Roé Crespo, I Sánchez-Carpintero, et al.
Actas Dermo-Sifiliograficas|August 6, 2014
Immune-mediated inflammatory diseases and other comorbidities in patients with psoriasis: baseline characteristics of patients in the AQUILES studyF Vanaclocha, V Crespo-Erchiga, R Jiménez-Puya, et al.
The British Journal of Dermatology|October 15, 2013
Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)C Paul, L Puig, K Kragballe, et al.
The British Journal of Dermatology|September 18, 2016
Biosimilars for psoriasis: clinical studies to determine similarityA Blauvelt, L Puig, S Chimenti, et al.
The British Journal of Dermatology|October 15, 2013
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasisK Reich, L Puig, C Paul, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 14, 2018
Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissuesJoshua A Kulas, Whitney F Franklin, Nicholas A Smith, et al.
Actas Dermo-Sifiliograficas|May 26, 2009
[Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology]L Puig, X Bordas, J M Carrascosa, et al.
The British Journal of Dermatology|September 19, 2012
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical settingR Navarro, E Vilarrasa, P Herranz, et al.
Environmental Pollution (Barking, Essex : 1987)|May 30, 2018
In utero exposure to fine particulate matter results in an altered neuroimmune phenotype in adult miceJoshua A Kulas, Jordan V Hettwer, Mona Sohrabi, et al.
The British Journal of Dermatology|June 21, 2019
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeksK Reich, R B Warren, L Iversen, et al.
Pageof 43